CTI BioPharma Total Liabilities

CTI BioPharma's total liabilities stands at $140M as of March 2023. That compares with $160M in the prior-year period — down 13.6% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

CTI BioPharma reported $140M in total liabilities versus $160M a year earlier — a 13.6% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $160M in the prior-year period — down 13.6% year over year. Sustained growth in total liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how CTI BioPharma's total liabilities evolved across reporting periods, while the comparison chart places CTIC next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, total liabilities is commonly used to spot outliers. CTI BioPharma's reading of $140M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.